- 1 Cell type profile variation in menstrual effluent by sample collection method identified 2 using methylation cytometry 3 Authors: Irma M. Vlasac¹, Hannah G. Stolrow¹, Zaneta M. Thayer², Brock C. 4 Christensen^{1,3}. Luisa Rivera² 5 6 ¹ Department of Epidemiology, Geisel School of Medicine at Dartmouth, Lebanon, NH 7 03756, USA 8 ² Department of Anthropology, Dartmouth College, Hanover, NH 03755, USA 9 10 ³ Department of Molecular and Systems Biology, Geisel School of Medicine at 11 Dartmouth, Lebanon, NH 03756, USA 12 Abstract 13 Menstrual effluent cell profiles have potential as noninvasive biomarkers of female 14 15 reproductive and gynecological health and disease. We used DNA methylation-based cell type deconvolution (methylation cytometry) to identify cell type profiles in self-16 collected menstrual effluent. During the second day of their menstrual cycle healthy 17 participants collected menstrual effluent using a vaginal swab, menstrual cup, and pad. 18 Immune cell proportions were highest in menstrual cup samples, and epithelial cells 19 20 were highest in swab samples. Our work demonstrates the feasibility and utility of 21 menstrual effluent cell profiling in population-level research using remotely collected 22 samples and DNA methylation.
- 23

24 Introduction

25 Human females with access to birth control menstruate approximately 400 times during their reproductive lifespan¹, from menarche in early adolescence around 12 years of 26 27 age, continuing until menopause at approximately 40-50 years of age. Menstruation is a 28 result of a complex and highly specific system regulated hormonally through the 29 hypothalamus, pituitary, and ovarian endocrine axis, and disruption to the menstrual 30 cycle can be indicative of underlying health issues. As an example, irregular and long 31 menstrual cycles are associated with a range of adverse conditions, including ovarian cancer² and greater risk of premature mortality³. Menstrual effluent is comprised of the 32 33 shed uterine lining developed during the secretory phase of the menstrual cycle as well as cells from the cervix and vagina. As such, menstrual effluent may be a powerful proxy tissue for the 34 35 endometrium, with recent work finding considerable overlap between menstrual and endometrial cytokine levels, cellular composition, and gene expression profiles^{4,5}. Research 36 37 on menstrual effluent has begun to investigate its potential as an informative 38 biospecimen in women's health research. Studies to date have focused on elucidating 39 inflammatory profiles and identifying perinatal biomarkers of fertility and endometriosis^{5–7}, and as a determinant of adverse pregnancy outcomes. In addition, 40 despite significant disease burden there are no current non-invasive screening tools for 41 42 ovarian cancer, endometrial cancer, or endometriosis. 43

Methylation cytometry methods can determine the cell-type admixture of biospecimens
with cell reference profiles of DNA methylation and statistical deconvolution. Methylation
cytometry methods exist for multiple biospecimen types but have not been applied to

47	menstrual effluent. The hierarchical tumor immune microenvironment epigenetic
48	deconvolution (HiTIMED) algorithm quantifies up to 17 cell types and can be used to
49	estimate cell types in both tumor and non-tumor normal tissues ⁸ . HiTIMED developed
50	20 tissue-specific cell reference deconvolution libraries, including endometrial tissue,
51	from which menstrual effluent is shed directly from the endometrium of the uterus. We
52	demonstrate the utility and feasibility of DNA-based cell type profiling in menstrual
53	effluent in healthy females across three collection methods: menstrual cup, menstrual
54	pad, and vaginal swab.
55	
56	Materials and Methods
57	
58	Study Participants and Samples
58 59	Study Participants and Samples Healthy study participants (n=12) were recruited through campus flyers, online
58 59 60	Study Participants and Samples Healthy study participants (n=12) were recruited through campus flyers, online communities, and in-person recruitment as part of an IRB-approved study at Dartmouth
58 59 60 61	Study Participants and Samples Healthy study participants (n=12) were recruited through campus flyers, online communities, and in-person recruitment as part of an IRB-approved study at Dartmouth College. Written consent was obtained, and study participants were screened based on
58 59 60 61 62	Study Participants and Samples Healthy study participants (n=12) were recruited through campus flyers, online communities, and in-person recruitment as part of an IRB-approved study at Dartmouth College. Written consent was obtained, and study participants were screened based on the following eligibility criteria: 18 years of age and older, regular menstrual cycles, no
58 59 60 61 62 63	Study Participants and Samples Healthy study participants (n=12) were recruited through campus flyers, online communities, and in-person recruitment as part of an IRB-approved study at Dartmouth College. Written consent was obtained, and study participants were screened based on the following eligibility criteria: 18 years of age and older, regular menstrual cycles, no current use of hormonal birth control, no history of reproductive disorders (PCOS,
58 59 60 61 62 63 64	Study Participants and Samples Healthy study participants (n=12) were recruited through campus flyers, online communities, and in-person recruitment as part of an IRB-approved study at Dartmouth College. Written consent was obtained, and study participants were screened based on the following eligibility criteria: 18 years of age and older, regular menstrual cycles, no current use of hormonal birth control, no history of reproductive disorders (PCOS, endometriosis, adenomyosis, gynecologic cancers), and no immunomodulatory therapy.
58 59 60 61 62 63 64 65	Study Participants and Samples Healthy study participants (n=12) were recruited through campus flyers, online communities, and in-person recruitment as part of an IRB-approved study at Dartmouth College. Written consent was obtained, and study participants were screened based on the following eligibility criteria: 18 years of age and older, regular menstrual cycles, no current use of hormonal birth control, no history of reproductive disorders (PCOS, endometriosis, adenomyosis, gynecologic cancers), and no immunomodulatory therapy. Participants completed two questionnaires: health history, and menstrual questionnaire
58 59 60 61 62 63 64 65 66	Study Participants and Samples Healthy study participants (n=12) were recruited through campus flyers, online communities, and in-person recruitment as part of an IRB-approved study at Dartmouth College. Written consent was obtained, and study participants were screened based on the following eligibility criteria: 18 years of age and older, regular menstrual cycles, no current use of hormonal birth control, no history of reproductive disorders (PCOS, endometriosis, adenomyosis, gynecologic cancers), and no immunomodulatory therapy. Participants completed two questionnaires: health history, and menstrual questionnaire completed at the time of sample collection. Study kits were mailed to participants and
58 59 60 61 62 63 64 65 66 67	Study Participants and Samples Healthy study participants (n=12) were recruited through campus flyers, online communities, and in-person recruitment as part of an IRB-approved study at Dartmouth College. Written consent was obtained, and study participants were screened based on the following eligibility criteria: 18 years of age and older, regular menstrual cycles, no current use of hormonal birth control, no history of reproductive disorders (PCOS, endometriosis, adenomyosis, gynecologic cancers), and no immunomodulatory therapy. Participants completed two questionnaires: health history, and menstrual questionnaire completed at the time of sample collection. Study kits were mailed to participants and

were instructed to collect samples on the second day of their period, defined as thesecond day following the onset of bleeding.

71

72 For swab collection, participants were instructed to insert the swab (*Puritan HydraFlock*, 73 #25-3406-H) into their vagina and hold for 15 seconds or until completely saturated. The 74 swab was placed in a 4 mL self-standing centrifuge tube containing 2 mL of DNA/RNA 75 shield (*Zymo*, #R1100-250). This process was repeated twice for the collection of two 76 swabs. To collect the pad sample, participants were provided with an organic cotton 77 liner (natracare, #3145), with a cut 2 x 2-inch square liner secured on top. Participants 78 were instructed to wear the liner until the square was completely saturated, which was 79 estimated to take approximately 5 minutes but may have varied amongst participants. 80 Once the square was saturated, using the provided tweezers, participants removed the 81 saturated square and placed it in a 4 mL self-standing centrifuge tube containing 2 mL 82 of DNA/RNA shield (Zymo, # R1100-250). The menstrual cup (NeoProMedical, 83 #B092DTN2XS) was worn for sample collection after which a disposable pipette was 84 used to aliquot 2 mL of menstrual effluent into a 4 mL self-standing centrifuge tube 85 containing 2 mL of DNA/RNA shield (Zymo, #R1100-250). Participants were instructed 86 to wear nitrile gloves for all collection modes and place samples in a biohazard 87 collection bag before packaging them in the return box. 88

89 DNA Extraction and Methylation Analysis

90 DNA was extracted from menstrual cup samples using Qiagen DNeasy Blood and

91 Tissue kit protocol, following manufacturers protocol for extraction from blood samples.

92 DNA was extracted from menstrual pads by cutting a 1x1 centimeter piece of the 93 saturated menstrual pad sample, then using it as the base material for extraction using 94 the Qiagen DNA Investigator's Kit. DNA was extracted from vaginal swab samples by 95 removing the swab from the plastic swab base, then using the swab material as the 96 base material for extraction using the Qiagen DNA Investigator's Kit. DNA was extracted 97 from a total of 36 samples, three samples per participant with 12 participants assessed 98 in total. Extracted DNA samples were bisulfite modified using the EZ DNAm Kit (Zymo 99 Research) following the manufacturers optimized protocol for Illumina Methylation arrays⁹. Bisulfite converted DNA was arrayed on the Infinium MethylationEPIC 100 101 BeadChip V2 array at the Dartmouth Cancer Center Genomics and Molecular Biology 102 Shared Resource.

103

104 Data Processing and Quality Control

105 MethylationEPICv2 Intensity data (IDATs) were preprocessed for normal exponential out-of-band (Noob) correction using Minfi¹⁰. Quality control was performed using a 106 107 detection P, CpG, and sample threshold of 5%, with zero samples demonstrating a 108 percentage of low quality CpG values greater than 5%. Beta value technical replicates 109 were collapsed by averaging probes with common probe ID prefixes using SeSAMe¹¹. 110 Single nucleotide polymorphisms (SNPs), probes were used as a quality control metric 111 to assess concordance amongst sample type and participant. Non-CpG cytosine 112 methylation, cancer somatic mutation probes, and probes located on sex chromosomes were filtered. Beta values were normalized using beta mixture quantile normalization 113 114 (BMIQ). For quality control, sample matching was confirmed using SNP probes.

115

116 Statistical Analysis

- 117 Cell proportions were estimated using Hierarchical Immune Tumor Deconvolution
- (HiTIMED)⁸, designated at deconvolution level four, set to non-tumor normal tissue with
- the uterine carcinoma deconvolution library. Cell proportions from each sample type
- 120 (menstrual pad, menstrual cup, vaginal swab) were assessed for significant differences
- 121 between the three collection sample types using a Kruskal-Wallis test. Unsupervised
- hierarchical clustering was performed using the top 20,000 most variable CpGs. A
- 123 Recursively Partitioned Mixture Model (RPMM)¹² was fit using the 20,000 most variably
- methylated CpGs to identify subgroups within the methylation data. Association of
- 125 RPMM cluster membership with sample collection method was tested with a Fisher's
- 126 exact test.
- 127

128 **Results**

129 DNA methylation data from each collection method matched to a total of twelve study 130 participants (Supplementary Table 1) was visualized with unsupervised hierarchical 131 clustering of the 20,000 most variably methylated CpGs (Figure 1A). To test 132 associations of methylation with sample collection method, a recursively partitioned 133 mixture model was fit to the 20,000 most variably methylated CpGs (Figure 1B), resulting in four clusters. The majority of cup samples (75%) were in cluster rRR, and 134 135 sample collection method was significantly associated with methylation cluster 136 membership (Fisher's Exact P=3.9E-05, Figure 1C).

E

Ë

님

ñ



Sample Type (n%)

Pad

8

6

14

6

Cup

0

0

8

25

Swab

19

11

3

0



С

Cluster

rLL

rLR

rRL

rRR

Figure 1. A) Unsupervised hierarchical clustering based on top 20,000 most variable
CpGs. B) Recursively Partitioned Mixture Model (RPMM) with mean methylation
displayed in each of the four clusters. C) table of RPMM cluster membership by sample
type.

Fishers Exact Test

p-value

3.91E-05

145

Menstrual effluent cell type proportions were estimated using HiTIMED in all samples and compared among collection methods. Epithelial and stromal cell proportions were significantly higher in swab samples compared to pad samples, with cup samples demonstrating the lowest epithelial and stromal cell proportions; cup samples had significantly higher granulocyte, natural killer, and T cell proportions compared to swab samples (P <0.05, Kruskal-Wallis test, **Figure 2**).





Figure 2. Menstrual effluent cell type proportions differ among menstrual cup, menstrual
 pad, and vaginal swab collection methods as determined by methylation cytometry.

157 Discussion

158 Our work demonstrates the utility of cell type profiling in menstrual effluent with 159 methylation cytometry for research applications in female reproductive and 160 gynecological health and disease. Methylation cytometry cell deconvolution analysis 161 identified cell type proportion differences by sample collection method. Menstruation is a 162 process of tissue inflammation and is marked by an increase in myeloid immune cells 163 and leukocytes recruited in response to inflammation from necrotizing and shedding tissue^{13,14}. Menstrual cup samples had the highest immune cell proportions, specifically 164 165 granulocyte, natural killer, and T cell proportions in comparison to menstrual pad and

166 vaginal swab samples. Considering diseases marked by abnormally high inflammation, 167 such as endometriosis, future studies utilizing menstrual effluent should consider 168 collection method as it relates with the study goals and hypotheses. Studies aimed at 169 elucidating immune cell profiles with gynecologic health and disease may be better 170 powered to discern effects with menstrual cup and pad collection methods. Similarly, 171 studies which may be more focused on assessing conditions that affect epithelial and 172 stromal cells of the cervix or vagina, may favor menstrual pads or vaginal swabs for 173 sample collection. In any case, application of methylation cytometry methods enables 174 investigation of cell-type-dependent and cell-type-independent associations with health 175 and disease.

176

177 We expected cell type proportion differences based on collection method similarly to 178 how we observed them. The vaginal swab collection method had higher epithelial cell 179 proportions, which is likely related to the method of sample collection considering the 180 participant collected the sample shallowly within the vaginal canal as opposed to closer 181 to the cervix. Similarly, the menstrual pad collection likely demonstrates higher epithelial 182 cell proportions considering the shed menstrual effluent travels through the vaginal 183 canal and vulva before being absorbed on the menstrual pad. While menstrual cup 184 sample collections demonstrate the highest immune cell proportions compared to other 185 sample collection methods, menstrual effluent collected by menstrual pad holds great 186 promise for future research studies given it captures cell types from the immune, epithelial, and stromal cell compartments. Considering menstrual pad collection is the 187 188 only method of collection that doesn't require insertion, it allows for a truly non-invasive,

non-penetrative sample collection, allowing for sample collection from adolescents and 189 190 individuals that may not want to use an insertional collection method. As menstrual pads can easily and inexpensively be shipped in the mail and are widely available, they may 191 192 provide greater potential in the scope of population level studies and studies conducted 193 in resource limited populations. Use of DNA-based cell typing in menstrual effluent 194 samples combined with remote, noninvasive sampling methods potentiate both 195 research and future clinical applications of menstrual effluent specimens that benefit 196 women's health.

197

198 Supplementary Table 1

Characteristic	Participants (N = 12)	
Age (%)		
18 - 25	7 (58.3)	
26 - 35	2 (16.7)	
> 35	3 (25.0)	
Average Age	27	
Parity (%)		
Nulliparous	8 (66.7)	
Multiparous	4 (33.3)	
Menstrual Pain (%)		
Not painful	1 (8.3)	
A little painful	4 (33.3)	
Somewhat painful	6 (50.0)	
Very painful	1 (8.3)	
Recent Illness (%)		
No	11 (91.7)	
Yes	1 (8.3)	
Pain Medication (%)		
None	9 (75.0)	
Ibuprofen	3 (25.0)	

200

199

201

202 **Declarations**

204	Ethics approval	and consent f	o partici	pate
-----	-----------------	---------------	-----------	------

- 205
- 206 Availability of data and materials
- 207
- 208 <u>Funding</u>
- 209
- 210
- 211 Author's contributions
- 212 LR and ZMT designed the study. IMV and HGS processed samples. IMV performed the
- analysis and drafted the manuscript. All authors contributed to and approved the final
- 214 manuscript. Thank you to Claire Pingitore and Sovi Mya-Wellons for their assistance in
- assembling and sending study kits.
- 216
- 217

218 **References**

- 1. Jabbour, H. N., Kelly, R. W., Fraser, H. M. & Critchley, H. O. D. Endocrine Regulation
 of Menstruation. *Endocrine Reviews* 27, 17–46 (2006).
- 221 2. Cirillo, P. M., Wang, E. T., Cedars, M. I., Chen, L. & Cohn, B. A. Irregular menses
- 222 predicts ovarian cancer: Prospective evidence from the Child Health and
- 223 Development Studies. International Journal of Cancer **139**, 1009–1017 (2016).
- 3. Wang, Y.-X. et al. Menstrual cycle regularity and length across the reproductive
- lifespan and risk of premature mortality: prospective cohort study. *BMJ* **371**, m3464
- 226 (2020).

- 4. Tortorella, C. *et al.* Interleukin-6, interleukin-1 β , and tumor necrosis factor α in
- 228 menstrual effluents as biomarkers of chronic endometritis. *Fertility and Sterility* **101**,

229 242–247 (2014).

- 5. Warren, L. A. et al. Analysis of menstrual effluent: diagnostic potential for
- endometriosis. *Molecular Medicine* **24**, 1 (2018).
- 232 6. Naseri, S., Rosenberg-Hasson, Y., Maecker, H. T., Avrutsky, M. I. & Blumenthal, P. D.
- A cross-sectional study comparing the inflammatory profile of menstrual effluent vs.
- peripheral blood. *Health Science Reports* **6**, e1038 (2023).
- 235 7. Nayyar, A. et al. Menstrual Effluent Provides a Novel Diagnostic Window on the
- 236 Pathogenesis of Endometriosis. *Frontiers in Reproductive Health* **2**, (2020).
- 237 8. Zhang, Z. et al. HiTIMED: hierarchical tumor immune microenvironment epigenetic
- deconvolution for accurate cell type resolution in the tumor microenvironment using
- tumor-type-specific DNA methylation data. *Journal of Translational Medicine* 20, 516
 (2022).
- 241 9. Campan, M., Weisenberger, D. J., Trinh, B. & Laird, P. W. MethyLight. *Methods Mol*242 *Biol* 507, 325–337 (2009).
- Aryee, M. J. *et al.* Minfi: a flexible and comprehensive Bioconductor package for
 the analysis of Infinium DNA methylation microarrays. *Bioinformatics* **30**, 1363–1369
 (2014).
- Z46 11. Zhou, W., Triche, T. J., Jr, Laird, P. W. & Shen, H. SeSAMe: reducing artifactual
 detection of DNA methylation by Infinium BeadChips in genomic deletions. *Nucleic Acids Research* 46, e123 (2018).

- 249 12. Koestler, D. C., Marsit, C. J., Christensen, B. C., Kelsey, K. T. & Houseman, E. A.
- A recursively partitioned mixture model for clustering time-course gene expression
- data. *Translational cancer research* **3**, 217 (2014).
- 252 13. Salamonsen, L. A. Tissue injury and repair in the female human reproductive
- 253 tract. *Reproduction* **125**, 301–311 (2003).
- 14. Finn, C. A. Implantation, Menstruation and Inflammation. *Biological Reviews* 61,
- 255 313–328 (1986).
- 256
- 257
- 258